Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Vassal

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|May 7, 1999
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institutionO Hartmann, D Valteau-Couanet, G Vassal, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantationG Vassal, S Koscielny, D Challine, et al.
British Journal of Cancer|February 22, 2000
p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell lineC Badie, J Bourhis, J Sobczak-Thépot, et al.
British Journal of Cancer|March 10, 1999
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrationsI Boland, G Vassal, J Morizet, et al.
Medical and Pediatric Oncology|January 1, 1991
Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987A Suarez, O Hartmann, G Vassal, et al.
Oncogene|February 28, 2006
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecanL Calvet, B Geoerger, M Regairaz, et al.
Bone Marrow Transplantation|December 1, 1991
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphomaH A Loiseau, O Hartmann, D Valteau, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbitsL H Ramirez, Z Zhao, P Rougier, et al.
Blood|August 1, 1993
Busulfan disposition below the age of three: alteration in children with lysosomal storage diseaseG Vassal, A Fischer, D Challine, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2012
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trialG J Veal, L Nguyen, A Paci, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|May 7, 1999
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institutionO Hartmann, D Valteau-Couanet, G Vassal, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantationG Vassal, S Koscielny, D Challine, et al.
British Journal of Cancer|February 22, 2000
p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell lineC Badie, J Bourhis, J Sobczak-Thépot, et al.
British Journal of Cancer|March 10, 1999
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrationsI Boland, G Vassal, J Morizet, et al.
Medical and Pediatric Oncology|January 1, 1991
Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987A Suarez, O Hartmann, G Vassal, et al.
Oncogene|February 28, 2006
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecanL Calvet, B Geoerger, M Regairaz, et al.
Bone Marrow Transplantation|December 1, 1991
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphomaH A Loiseau, O Hartmann, D Valteau, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbitsL H Ramirez, Z Zhao, P Rougier, et al.
Blood|August 1, 1993
Busulfan disposition below the age of three: alteration in children with lysosomal storage diseaseG Vassal, A Fischer, D Challine, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2012
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trialG J Veal, L Nguyen, A Paci, et al.
Pageof 10